This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
KnieB.MitraM.T.LogishettyK.ChaudhuriK.R.Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs.2011; 25(3): 203–212.
2.
MorgenthalerT.I.KapurV.K.BrownT.; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep.2007; 30(12): 1705–1711.
3.
FerreiraJ.J.KatzenschlagerR.BloemB.R.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol.2013; 20(1): 5–15.
4.
HoglB.SaletuM.BrandauerE.Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep.2002; 25: 905–909.
5.
AdlerC.H.CavinessJ.N.HentzJ.G.LindM.TiedeJ.Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord.2003; 18: 287–293.
6.
OndoW.G.FayleR.AtassiF.JankovicJ.Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry.2005; 76(12): 1636–1639.
7.
LouJ.S.DimitrovaD.M.ParkB.S.JohnsonS.C.EatonR.ArnoldG.NuttJ.G.Using modafinil to treat fatigue in Parkinson disease: A double-blind, placebo-controlled pilot study. Clin Neuropharmacol.2009; 32(6): 305–310.
8.
NievesA.V.LangA.E.Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol.2002; 25: 111–114.
9.
LökkJ.Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study. Neuropsychiatr Dis Treat.2010; 6: 93–97.
10.
RabinsteinA.ShulmanL.M.WeinerW.J.Modafinil for the treatment of excessive daytime sleepiness in Parkinson's disease: A case report. Parkinsonism Relat Disord.2001; 7: 287–288.
11.
HappeS.PirkerW.SauterC.KloschG.ZeitlhoferJ.Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol.2001; 248: 632–634.
12.
ZesiewiczT.A.SullivanK.L.ArnulfI.ChaudhuriK.R.MorganJ.C.GronsethG.S.MiyasakiJ.IversonD.J.WeinerW.J.; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2010; 74(11): 924–931.
13.
GrimesD.GordonJ.SnelgroveB.; Canadian Neurological Sciences Federation. Canadian guidelines on Parkinson's disease. Can J Neurol Sci.2012; 39(4 Suppl 4): S1–30.
14.
Scottish Intercollegiate Guidelines Network. Diagnosis and Pharmacological Management of Parkinson's Disease. A National Clinical Guideline.Edinburgh: SIGN; January 2010.
